MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Gilead Sciences Inc.

Cerrado

SectorSalud

111.99 0.86

Resumen

Variación precio

24h

Actual

Mínimo

110.44

Máximo

111.99

Métricas clave

By Trading Economics

Ingresos

530M

1.8B

Ventas

29M

7.6B

P/B

Media del Sector

294.868

63.778

BPA

1.9

Rentabilidad por dividendo

2.82

Margen de beneficio

23.557

Empleados

17,600

EBITDA

-655M

3.1B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+3.64% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.82%

2.39%

Próximas Ganancias

24 abr 2025

Fecha Próximo Dividendo

26 jun 2025

Próxima Fecha de Ex Dividendo

13 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

18B

140B

Apertura anterior

111.13

Cierre anterior

111.99

Noticias sobre sentimiento de mercado

By Acuity

46%

54%

169 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Gilead Sciences Inc. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 feb 2025, 21:17 UTC

Ganancias

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

19 dic 2024, 15:25 UTC

Principales Movimientos del Mercado

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding

19 dic 2024, 13:38 UTC

Principales Movimientos del Mercado

Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead

6 nov 2024, 22:25 UTC

Ganancias

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

19 mar 2025, 14:50 UTC

Principales Noticias

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb 2025, 22:13 UTC

Charlas de Mercado
Ganancias

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 feb 2025, 21:06 UTC

Ganancias

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Raises Dividend 2.6%>GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Sees 2205 Veklury Sales $1.4B>GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences Sees 2025 Sales $28.2B-$28.6B >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q HCV Products Sales >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q Rev Up on HIV, Oncology, Liver Disease; Partially Offset by lower sales of Veklury (Remdesivir) >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q Adj EPS $1.90 >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q Rev $7.57B >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q EPS $1.42 >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q EPS $1.42 >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q Net $1.78B >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q Rev $7.6B >GILD

11 feb 2025, 21:02 UTC

Ganancias

Gilead Sciences 4Q Adj EPS $1.90 >GILD

10 ene 2025, 10:30 UTC

Principales Noticias

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

29 dic 2024, 08:00 UTC

Adquisiciones, fusiones, absorciones

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com

19 dic 2024, 13:23 UTC

Principales Movimientos del Mercado

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

7 nov 2024, 16:23 UTC

Ganancias

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise -- IBD

Comparación entre iguales

Cambio de precio

Gilead Sciences Inc. Esperado

Precio Objetivo

By TipRanks

3.64% repunte

Estimación a 12 meses

Media 115.33 USD  3.64%

Máximo 140 USD

Mínimo 90 USD

De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gilead Sciences Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

23 ratings

17

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

109.84 / 112.2Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

169 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.